Conference call and webcast to be held at 8:30 a.m. ET NEW HAVEN, Conn., June 1, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough...
Read More Details
Finally We wish PressBee provided you with enough information of ( Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough )
Also on site :
- ‘Up close and personal’ – Taylor Swift and Travis Kelce share intimate date night as onlooker gives insight into romance
- Bianca Censori Makes Major Career Move After Dropping Jaws With See-Through Outfit
- Exactly How Many Times a Week To Walk To Improve Your Heart Health, According to Cardiologists